CSL Behring – 'The Biggest Company Nobody Has Ever Heard Of' – Raises Its Voice
Executive Summary
CEO Paul Perreault tells 'The Pink Sheet' that flu business from Novartis, hemophilia drugs approaching approval, and pipeline blockbuster to prevent secondary heart attacks will transform profile of Australian biopharma.
You may also be interested in...
FDA Supports FluMist Use, Releases Lots For 2016 Flu Season
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.